Business Context and Reporting Period
Company: Denali Therapeutics Inc. (DNLI)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Denali is a clinical-stage biopharmaceutical company focused on developing barrier-crossing therapeutics for neurodegenerative and lysosomal storage diseases using its proprietary TransportVehicle (TV) platform. The company has no approved products and generates revenue solely through collaboration agreements.
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Collaboration Revenue | $0 | $0 | N/A |
| Research & Development Expenses | $418.8 million | $396.4 million | +6% |
| General & Administrative Expenses | $136.6 million | $105.4 million | +30% |
| Net Loss | $(512.5) million | $(422.8) million | +21% |
| Cash, Cash Equivalents & Marketable Securities | $966.2 million | $1,143.5 million | -15% |
| Accumulated Deficit | $(2.05) billion | $(1.54) billion | N/A |
Note: The company reported no product revenue. Collaboration revenue was $0 in 2025 and 2024, compared to $330.5 million in 2023.
Material Changes vs. Prior Period
- Increased Operating Expenses: Total operating expenses rose 11% to $555.3 million. R&D expenses increased primarily due to higher spend on TV programs (DNL126, DNL628, DNL952) and the commencement of operations at the new Salt Lake City manufacturing facility. G&A expenses increased 30% due to headcount growth in preparation for the potential commercial launch of tividenofusp alfa.
- Divestiture Gain Elimination: The $14.5 million non-cash gain from the divestiture of small molecule programs recorded in 2024 did not recur in 2025.
- Capital Raise: In December 2025, the company raised approximately $189.2 million through a public offering of common stock and pre-funded warrants. In January 2026, an additional $12.4 million was raised via the underwriters' option exercise.
- Collaboration Terminations: The company terminated the ATV:TREM2 program with Takeda and the CNS Products program with Sanofi in early 2025, eliminating future milestone revenue potential from these specific assets.
Guidance, Outlook, and Management Commentary
Strategic Outlook (D3X3 Strategy)
Management outlined a three-year strategy (2026-2028) to deliver two growing commercial brands (tividenofusp alfa and DNL126), achieve five clinical proof-of-concept readouts, and advance four to six new clinical programs.
Key Catalysts and Milestones
- tividenofusp alfa (DNL310): The Biologics License Application (BLA) for Hunter syndrome is under FDA priority review. The PDUFA target action date is April 5, 2026. The company has established commercial readiness.
- DNL126 (ETV:SGSH): For Sanfilippo syndrome type A, the company aligned with the FDA on a surrogate endpoint for accelerated approval. Phase 1/2 enrollment is complete, with preliminary data presented in February 2026.
- DNL952 (ETV:GAA): For Pompe disease, a clinical hold placed in December 2025 was lifted in January 2026. Phase 1 dosing is expected to initiate in 2026.
- Alzheimer's Programs: DNL628 (OTV:MAPT) and DNL921 (ATV:Abeta) are advancing toward Phase 1b/1 clinical studies in 2026.
Royalty Financing
In December 2025, Denali entered a synthetic royalty funding agreement with Royalty Pharma plc for up to $275.0 million in exchange for a 9.25% royalty on future net sales of tividenofusp alfa. Closing is contingent on FDA accelerated approval by June 30, 2026.
Risks and Contingencies
- Regulatory Risk: Failure to obtain FDA approval for tividenofusp alfa by the PDUFA date would impact the Royalty Pharma deal and commercial launch plans.
- Clinical Holds: The company experienced a temporary clinical hold on DNL952 in late 2025 due to preclinical hypersensitivity reactions, which was resolved via protocol amendments.
- Liquidity: Management believes current cash resources ($966.2 million) are sufficient to fund operations for at least the next 12 months.
Investor Verification Checklist
- BLA Status: Verify the FDA's decision on the tividenofusp alfa BLA by the April 5, 2026 PDUFA date.
- Royalty Pharma Closing: Confirm whether the $200 million initial payment from Royalty Pharma is received, contingent on the FDA approval timeline.
- Manufacturing Capacity: Assess the operational status and output of the new Salt Lake City clinical biomanufacturing facility.
- Collaboration Revenue: Monitor for any new milestone payments from Biogen (LRRK2 program) or Takeda (PTV:PGRN program), as no collaboration revenue was recognized in 2025.
- Cash Burn Rate: Track quarterly cash usage given the increased G&A spend for commercial preparation and the lack of product revenue.